Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors
November 13th 2022CYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung cancer, triple-negative breast cancer, and bladder cancer cell lines, according to preclinical data.
Read More
CTX130 Allogeneic CAR T-cell Therapy Shows Tolerability, Intriguing Activity in Advanced RCC
November 11th 2022CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.
Read More
Pembrolizumab/Eftilagimod alpha Combo Shows Durable Responses in Frontline NSCLC
November 11th 2022The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.
Read More
Neoantigen TCR T-cell Therapy Shows Early Proof-of-Concept in Solid Tumors
November 10th 2022A personalized neoantigen-specific and off-the-shelf T cell receptor T-cell therapy utilized through CRISPR gene editing technology demonstrated feasibility and tolerability in 16 patients across multiple tumor types, according to first-in-human phase 1a findings.
Read More
Amputation is an independent predictor of poor outcomes among patients with high-grade bone sarcoma of lower extremity, and non-private insurance was found to be linked with increased likelihood of amputation and an advanced stage at presentation in this patient population.
Read More
Enzalutamide/ADT Shows Long-Term Survival Benefit in mHSPC Regardless of Prior Local Treatment
May 14th 2022Enzalutamide added to androgen deprivation therapy demonstrated a benefit in overall survival, radiographic progression-free survival, undetectable prostate-specific antigen rates, objective response rates, and other end points vs placebo/ADT in patients with metastatic hormone-sensitive prostate cancer regardless of whether or not they received prior local therapy.
Read More
Niraparib Improves or Maintains HRQOL in Metastatic Castration-Resistant Prostate Cancer
May 7th 2022Niraparib was found to maintain or improve health-related quality of life in patients with advanced or metastatic castration-resistant prostate cancer, according to data from the final analysis of the phase 2 GALAHAD trial.
Read More
The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.
Read More
Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma
May 2nd 2022Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.
Read More
Addition of Ublituximab/Umbralisib to Ibrutinib Produces High uMRD Rate in CLL
May 2nd 2022The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)
Read More
Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL
April 26th 2022Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.
Read More
Treosulfan-Based Conditioning Improves Survival in Elderly, Comorbid Patients With AML
April 15th 2022Treatment with a treosulfan-based conditioning regimen led to a superior event-free and overall survival compared with busulfan-based conditioning in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation, according to a post-hoc subgroup analysis of the phase 3 MC-FludT.14/L trial.
Read More
Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets
April 13th 2022The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.
Read More
ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma
April 12th 2022The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.
Read More
Pegcetacoplan Improves Efficacy in Complement Inhibitor–Naïve Paroxysmal Nocturnal Hemoglobinuria
April 9th 2022Pegcetacoplan treatment was associated with hemoglobin stabilization and normalization, as well as a superior change from baseline in hemoglobin levels, which showed a meaningful correction of anemia, in patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
Read More
Checkpoint Blockade Before Allogeneic Transplant Improves PFS, But Not OS, in Hodgkin Lymphoma
April 7th 2022Checkpoint inhibitors prior to allogeneic hematopoietic cell transplant improved progression-free survival and relapse incidence in patients with Hodgkin lymphoma, but the treatment did not improve non-relapse mortality or overall survival.
Read More
Axi-Cel Shows Clinically Meaningful Improvement in QOL in Second-Line Relapsed/Refractory LBCL
March 23rd 2022Axicabtagene ciloleucel demonstrated a clinically improvement in quality of life compared with standard of care chemotherapy in the second-line setting for patients with relapsed/refractory large B-cell lymphoma.
Read More
IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer
March 20th 2022The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer
March 11th 2022The FDA has approved olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously received chemotherapy either before or after surgery.
Read More
Higher Doses of Ibrutinib/Venetoclax Not Linked With Higher Responses in Relapsed/Refractory MCL
March 8th 2022The combination of ibrutinib given at 420 mg and venetoclax at 200 mg elicited an objective response rate of 93.8% in patients with relapsed/refractory mantle cell lymphoma, according to results of a phase 1 dose-finding study.
Read More
Adjuvant CDK4/6 Inhibitors Demonstrate Success in Early-Stage HR+ Breast Cancer Development
March 4th 2022CDK4/6 inhibitors in the metastatic setting have demonstrated clinical benefit in the hormone receptor–positive breast cancer population, leading to curiosity of its activity in early-stage patients and setting the stage for a handful of informative clinical trials.
Read More
FDA Approves Pacritinib for Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia
March 1st 2022The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Read More